Targeted therapy for glioma using cyclic RGD-entrapped polyionic complex nanomicelles

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2853-2862

  Liu, Xiaoying ^a   Cui, Wenguo ^b   Li, Bo ^a   Hong, Zhen ^c  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Arg Gly Asp; Glioma; Micelle; Polyion complex; RGD; Target therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLO(ARGINYLGLYCYLASPARTIC ACID DEXTRO PHENYLALANYLCYSTEINE); NANOPARTICLE; QUANTUM DOT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL AGGREGATION; CELL MIGRATION; CELL VIABILITY; CHEMICAL BINDING; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; GLIOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MICELLE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PH; RAT; REACTION TIME; SALINITY; SURVIVAL TIME; ZETA POTENTIAL;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CADMIUM COMPOUNDS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; GLIOMA; HYDROGEN-ION CONCENTRATION; IMMUNOHISTOCHEMISTRY; MATERIALS TESTING; MICELLES; NEURONS; OLIGOPEPTIDES; QUANTUM DOTS; RATS; RATS, WISTAR; TELLURIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

RATTUS;

EID: 84870321183     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S29788     Document Type: Article

References (19)

1. Schneider T, Mawrin C, Scherlach C, Skalej M, Firsching R. Gliomas in adults. Dtsch Arztebl Int. 2010;107:799-807.
2. Larjavaara S, Mäntylä R, Salminen T, etal. Incidence of gliomas by anatomic location. Neuro Oncol. 2007;9:319-325.
3. Arosio D, Manzoni L, Araldi EM, Scolastico C. Cyclic RGD functionalized gold nanoparticles for tumor targeting. Bioconjug Chem. 2011;22:664-672.
4. Braun K, Wiessler M, Pipkorn R, etal. A cyclic-RGD-bioshuttle functionalized with TMZ by DARinv "Click Chemistry" targeted to αvβ3 integrin for therapy. Int J Med Sci. 2010;7:326-339.
5. Liu Z, Wang J, Yin P, etal. RGD-FasL induces apoptosis in hepatocellular carcinoma. Cell Mol Immunol. 2009;6:285-293.
6. Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R. Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol. 2011;7:339-354.
7. Kim YH, Jeon J, Hong SH, etal. Tumor targeting and imaging using cyclic RGD-PEGylated gold nanoparticle probes with directly conjugated iodine-125. Small. 2011;7:2052-2060.
8. Joralemon MJ, McRae S, Emrick T. PEGylated polymers for medicine: from conjugation to self-assembled systems. Chem Commun (Camb). 2010;46:1377-1393.
9. Zhou Y, Chakraborty S, Liu S. Radiolabeled cyclic RGD peptides as radiotracers for imaging tumors and thrombosis by SPECT. Theranostics. 2011;1:58-82.
10. Olivier JC, Huertas R, Lee HJ, Calon F, Pardridge WM. Synthesis of pegylated immunonanoparticles. Pharm Res. 2002;19:1137-1143.
11. Li Y, Owusu A, Lehnert S. Treatment of intracranial rat glioma model with implant of radiosensitizer and biomodulator drug combined with external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2004;58:519-527.
12. Matsuki K, Sasho T, Nakagawa K, etal. RGD peptide-induced cell death of chondrocytes and synovial cells. J Orthop Sci. 2008;13:524-532.
13. Smolarczyk R, Cichoń T, Graja K, Hucz J, Sochanik A, Szala S. Antitumor effect of RGD-4C-GG-D(KLAKLAK)2 peptide in mouse B16(F10) melanoma model. Acta Biochim Pol. 2006;53:801-805.
14. Hu Z, Luo F, Pan Y, etal. Arg-Gly-Asp (RGD) peptide conjugated poly(lactic acid)-poly(ethylene oxide) micelle for targeted drug delivery. Biomed Mater Res A. 2008;85:797-807.
15. Gilbert MR, Kuhn J, Lamborn KR, etal. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a Phase II trial with measures of treatment delivery. J Neurooncol. 2012;106:147-153.
16. Kim JH, Zheng LT, Lee WH, Suk K. Pro-apoptotic role of integrin β3 in glioma cells. J Neurochem. 2011;117:494-503.
17. Schnell O, Krebs B, Carlsen J, etal. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol. 2009;116:861-870.
18. Chen X, Park R, Khankaldyyan V, etal. Longitudinal microPET imaging of brain tumor growth with F-18-labeled RGD peptide. Mol Imaging Biol. 2006;8:9-15.
19. Zannetti A, Del Vecchio S, Iommelli F, etal. Imaging of alpha(v)beta(3) expression by a bifunctional chimeric RGD peptide not cross-reacting with alpha(v)beta(5). Clin Cancer Res. 2009;15:5224-5233.